Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPOSE: 177Lu-edotreotide versus best standard of care in SSTR-positive aggressive well-differentiated GEP-NETs
CTR20244669Phase 3Active
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Feb 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177-edotreotide in Gastroenteropancreatic Carcinoid Tumor, sponsored by ITM Isotope Technologies Munich. Started Feb 2025; status: active.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20244669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244669.